The report highlights the company's achievements in corporate social responsibility (CSR) in 2019, particularly in the areas of access to health care, environmental protection, and sustainability foundations. Key highlights include investing RMB 592 million in R&D and innovation, obtaining 7 new types of medicine added to the Essential Drug List, investing over RMB 22 million in environmental protection and energy saving, and achieving 100% rectification rate for all safety hazards discovered.
Issuing Company Baiyunshan Pharmaceutical Holdings Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 4.45 MB
No. of Pages 32 pages
Reporting periodJanuary 1, 2019-December 31, 2019
Report Edition12
Assurance Provider Unknown
Reporting Standards GRI; HKEx; SSE; others
Materiality Assessmenttrue